



February 12, 2019

To,
The Bombay Stock Exchange Ltd.
Pherozee Jeebhoy Towers,
Dalal Street
Mumbai -400001

Sub: Outcome of the Board Meeting- Unaudited quarterly financial results for the Third quarter and nine months ended 31st December, 2018

Ref: Intimation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Company Code - 530317

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are submitting herewith the copy of unaudited quarterly financial results for the quarter and nine months ended 31st December, 2018 along with the Limited Review Report thereon adopted at the Board meeting held on 12th February, 2019.

You are requested to kindly take the same on record.

Thanking you,
Yours Sincerely,

For Godavari Drugs Limited

Jeevan Innani
Company Secretary & Compliance Officer



**Encl: 1) Unaudited Financial Results of the Company
2) Limited Review Report**

GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	2467.39	1806.38	1425.43	5887.90	4385.29	6444.77
2	Other Income	9.73	0.12	36.55	12.44	57.31	67.69
3	Total Revenue from operations (1+2)	2477.12	1806.50	1461.98	5900.34	4442.60	6512.46
4	Expenses						
	(a) Cost of materials consumed	2069.45	1143.75	1345.15	4664.75	3363.68	4818.03
	(b) Changes in inventories of finished goods & work-in-progress	-73.72	216.87	-292.25	-151.58	-51.52	109.06
	(c) Employee benefits expense	87.50	77.58	66.98	238.12	196.23	266.76
	(d) Depreciation & amortization expense	27.76	27.27	24.00	80.80	71.74	98.53
	(e) Finance Costs	68.66	82.90	56.76	223.81	170.46	241.80
	(f) Other Expenses	239.20	231.51	212.43	738.30	619.85	846.90
	Total expenses	2418.85	1779.88	1413.07	5794.20	4370.44	6381.08
5	Profit before exceptional Items and tax (3-4)						
6	Exceptional items						
7	Profit before Tax (5-6)	58.27	26.62	48.91	106.14	72.16	131.38
8	Tax expense	-11.59	-6.11	-16.14	-21.64	-22.94	-48.44
9	Net Profit for the period (7-8)	46.68	20.51	32.77	84.50	49.22	82.94
10	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	-
11	Total Comprehensive Income (9+10)	46.68	20.51	32.77	84.50	49.22	82.94
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity						951.83
14	Earnings per share (of Rs.10/- each) (not annualized)						
	(a) Basic	0.62	0.27	0.44	1.12	0.65	1.10
	(b) Diluted	0.62	0.27	0.44	1.12	0.65	1.10

Notes:

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 12th February 2019.
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33(3)© of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
- The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.



For GODAVARI DRUGS LIMITED

K.K.Jain

K.K.Jain

Director Finance

DIN: 00076657

Place: Secunderabad

Date: 12-02-2019

V. SRIDHAR & CO.

CHARTERED ACCOUNTANTS

Limited Review Report for Godavari Drugs Limited for the Quarter and Nine Months

Ended December 31, 2018.

To,

The Board of Directors

Godavari Drugs Limited

Secunderabad

We have reviewed the accompanying statements of unaudited financial results of M/s Godavari Drugs Limited(Company) for the quarter and nine months ended December 31, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors and has been prepared in accordance with the principles laid down under Section 133 of the Companies Act, 2013 read with rules issued there under and other Accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)



Regulations, 2015 read with Circular No CIR/CFD/CMD/15/2015 dated November 30, 2015 and CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.


We have reviewed the financial results and other information presented in accordance with IND AS for the quarter and nine months ended December 31, 2018 and have been presented solely on the basis of information complied by the Management.

For

For V.Sridhar & Co.,

Chartered Accountants

FRN No. 006206S



(V. Sridhar)

Partner

ICAI Membership No.202337

Hyderabad

February, 12th 2019